Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 53
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Neurosci Lett ; 751: 135797, 2021 04 23.
Artículo en Inglés | MEDLINE | ID: mdl-33727127

RESUMEN

Insulin-like growth factor (IGF)-2 is a multifunctional hormone with structural and functional similarity to IGF-1 in mammals and chickens. We previously showed that intracerebroventricular administration of IGF-1 suppresses food intake in chicks. Also, central administration of IGF-2 suppresses food intake in rats. In the present study, we evaluated whether IGF-2 is involved in the regulation of food intake in chicks. We also examined the effects of fasting on the mRNA levels of IGF binding proteins (IGFBPs) in the liver and hypothalamus, because IGFBPs bind IGF-1 and -2 in plasma and block their binding to the receptors, and locally expressed IGFBPs also influence IGFs binding to the receptors in mammals. Intracerebroventricular administration of IGF-2 significantly suppressed food intake in chicks. The mRNA levels of IGFBPs in the hypothalamus were not affected by six hours of fasting. On the other hand, six hours of fasting markedly increased the mRNA levels of hepatic IGFBP-1 and -2 (5.47- and 6.95-fold, respectively). The mRNA levels of IGFBP-3 were also significantly increased (1.36-fold) by six hours of fasting, whereas the mRNA levels of IGF-2, IGFBP-4, and -5 were unchanged. These findings suggest that circulating IGF-2 may be involved in satiety signals, but its physiological role may be regulated by IGFBPs production in the liver in chicks.


Asunto(s)
Pollos/fisiología , Ingestión de Alimentos/efectos de los fármacos , Factor II del Crecimiento Similar a la Insulina/farmacología , Animales , Proteínas Aviares/genética , Proteínas Aviares/metabolismo , Pollos/metabolismo , Ayuno/metabolismo , Hipotálamo/metabolismo , Inyecciones Intraventriculares , Proteína 1 de Unión a Factor de Crecimiento Similar a la Insulina/genética , Proteína 1 de Unión a Factor de Crecimiento Similar a la Insulina/metabolismo , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Hígado/metabolismo , Masculino , ARN Mensajero/genética , ARN Mensajero/metabolismo
2.
Biol Reprod ; 104(3): 602-610, 2021 03 11.
Artículo en Inglés | MEDLINE | ID: mdl-33348377

RESUMEN

Insulin-like growth factors (IGFs) are known for their involvement in endocrine and paracrine regulation of ovarian function. Although IGF2 is the predominant circulating and intraovarian form of IGFs in primate species, the stage-specific follicular expression, action, and regulation of IGF2 are not well defined. Therefore, experiments were conducted to investigate the follicular IGF production in response to steroid hormone regulation and the direct IGF actions on follicular development and function in vitro. Preantral follicles were isolated from rhesus macaque ovaries and cultured to the antral stage in media supplemented with follicle-stimulating hormone and insulin. Follicles were randomly assigned to treatment groups: (a) control, (b) trilostane (a steroid synthesis inhibitor), (c) trilostane + estradiol, (d) trilostane + progesterone, and (e) trilostane + dihydrotestosterone. Media was analyzed for IGF concentrations, which were correlated to follicle growth. Follicles produced IGF2, but not IGF1, at the antral stage. Steroid depletion decreased, whereas steroid replacement increased, IGF2 production by antral follicles. Media IGF2 levels correlated positively with antral follicle diameters. Macaque preantral follicles and granulosa cells were subsequently cultured without (control) and with recombinant human IGF2 supplementation. Follicle survival, growth, and paracrine factor production, as well as granulosa cell proliferation and gonadotropin receptor gene expression, were assessed. IGF2 addition increased follicle survival rates, diameters and inhibin B production, as well as granulosa cell proliferation. These data demonstrate that IGF2 produced by antral follicles, in response to steroid hormone regulation, could act as a paracrine factor that positively impacts preantral follicle development and function in primates.


Asunto(s)
Factor II del Crecimiento Similar a la Insulina/metabolismo , Factor II del Crecimiento Similar a la Insulina/farmacología , Folículo Ovárico/crecimiento & desarrollo , Folículo Ovárico/metabolismo , Animales , Relación Dosis-Respuesta a Droga , Estradiol/análogos & derivados , Estradiol/farmacología , Femenino , Hormona Folículo Estimulante/farmacología , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Macaca mulatta , Progesterona/farmacología , Técnicas de Cultivo de Tejidos
3.
J Stroke Cerebrovasc Dis ; 29(10): 105128, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32912509

RESUMEN

BACKGROUND: The insulin-like growth factor 2 (IGF-2) is a growth factor and anti-inflammatory cytokine that plays a crucial role in memory consolidation. However, the precise role of this factor in acute brain damage is still unclear. The present study aimed to evaluate the variations in hippocampal IGF-2 distribution on different days and investigate the effect of recombinant IGF-2 on memory cell density, and IGF-2 distribution following acute hippocampal damage resulting from intracerebral hemorrhage (ICH). METHODS: ICH was induced by injection of 100 µL of autologous blood into the left hippocampus of 72 male Sprague-Dawley rats. Recombinant IGF-2 was injected into the damaged hippocampus 30 min post-induction of ICH in the ICH-IGF-2 group. Then, on postoperative days 1, 3, 7, and 14, samples of brain tissue were collected to perform histopathological and immunohistochemical examinations. RESULTS: The stereological study indicated that the volume of the hippocampus and the number of neurons had a significant reduction, and the infarct volume had a significant increase following ICH. Following the injection of IGF-2, a significant improvement was observed in stereological studies. Immunohistochemical data showed that IGF-2 distribution increased in the hippocampus on different days after ICH, and IGF-2 injection led to a dramatic reduction in this distribution. CONCLUSIONS: In summary, the gradual increase of endogenous IGF-2 as growth and anti-inflammatory factor following hemorrhagic stroke reveals a critical role of this factor in brain recovery after injury. Moreover, the injection of IGF-2 can prevent cell death and alleviate the damage caused by the hemorrhagic stroke.


Asunto(s)
Hemorragia Cerebral/tratamiento farmacológico , Hipocampo/efectos de los fármacos , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/administración & dosificación , Animales , Muerte Celular/efectos de los fármacos , Hemorragia Cerebral/metabolismo , Hemorragia Cerebral/patología , Hipocampo/metabolismo , Hipocampo/patología , Factor II del Crecimiento Similar a la Insulina/metabolismo , Masculino , Neuronas/metabolismo , Neuronas/patología , Fármacos Neuroprotectores/metabolismo , Ratas Sprague-Dawley , Proteínas Recombinantes/administración & dosificación , Factores de Tiempo , Distribución Tisular
4.
Int J Biol Macromol ; 159: 183-193, 2020 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-32353494

RESUMEN

As one of the most commonly used materials in liver tissue engineering, hydrogel has received much attention in recent years. In this work, we prepared a gelatin methacrylate (GelMA)/oxidized hyaluronic acid (OHA)/galactosylated chitosan (Gal-CS)/Fe (III)@TA@IGF-2 200 (TA200) hydrogel loaded with insulin-like growth factor 2 (IGF-2) for regeneration of damaged hepatocytes. Fe (III)@TA microspheres served as carrier to achieve sustained release of IGF-2 to promote hepatocytes regeneration. Galactose ligands could bind to the asialoglycoprotein receptor (ASGPR) on the surface of hepatocytes. Galactosylated chitosan could significantly increase the specific function of hepatocytes. The hydrogel we prepared had a storage modulus of 1100 Pa and was suitable for migration of hepatocytes. The release ratio of IGF-2 could reach up to 90% within 14 days. For carbon tetrachloride (CCl4) induced human hepatic stellate cell line LX2 damage, GelMA/OHA/Gal-CS/TA200 hydrogel could significantly improve the survival of LX2 cells. The expression of HNF-4α and transferrin was detected in LX2 cells treated with hydrogel, indicating that the specific function of the liver was also restored. In summary, the GelMA/OHA/Gal-CS/TA200 hydrogels could be used as new tissue engineering scaffolds for the construction of artificial livers.


Asunto(s)
Hepatocitos/efectos de los fármacos , Hidrogeles/química , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Regeneración Hepática , Microesferas , Receptor de Asialoglicoproteína/metabolismo , Línea Celular , Supervivencia Celular , Quitosano/análogos & derivados , Liberación de Fármacos , Gelatina/química , Factor Nuclear 4 del Hepatocito/metabolismo , Hepatocitos/metabolismo , Humanos , Ácido Hialurónico/análogos & derivados , Factor II del Crecimiento Similar a la Insulina/farmacología , Compuestos de Hierro/química , Metacrilatos/química , Unión Proteica , Transferrina/metabolismo
5.
Drug Deliv Transl Res ; 10(2): 425-439, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-31942701

RESUMEN

BMN 250 is being developed as enzyme replacement therapy for Sanfilippo type B, a primarily neurological rare disease, in which patients have deficient lysosomal alpha-N-acetylglucosaminidase (NAGLU) enzyme activity. BMN 250 is taken up in target cells by the cation-independent mannose 6-phosphate receptor (CI-MPR, insulin-like growth factor 2 receptor), which then facilitates transit to the lysosome. BMN 250 is dosed directly into the central nervous system via the intracerebroventricular (ICV) route, and the objective of this work was to compare systemic intravenous (IV) and ICV delivery of BMN 250 to confirm the value of ICV dosing. We first assess the ability of enzyme to cross a potentially compromised blood-brain barrier in the Naglu-/- mouse model and then assess the potential for CI-MPR to be employed for receptor-mediated transport across the blood-brain barrier. In wild-type and Naglu-/- mice, CI-MPR expression in brain vasculature is high during the neonatal period but virtually absent by adolescence. In contrast, CI-MPR remains expressed through adolescence in non-affected non-human primate and human brain vasculature. Combined results from IV administration of BMN 250 in Naglu-/- mice and IV and ICV administration in healthy juvenile non-human primates suggest a limitation to therapeutic benefit from IV administration because enzyme distribution is restricted to brain vascular endothelial cells: enzyme does not reach target neuronal cells following IV administration, and pharmacological response following IV administration is likely restricted to clearance of substrate in endothelial cells. In contrast, ICV administration enables central nervous system enzyme replacement with biodistribution to target cells.


Asunto(s)
Acetilglucosaminidasa/administración & dosificación , Acetilglucosaminidasa/genética , Barrera Hematoencefálica/química , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Mucopolisacaridosis III/tratamiento farmacológico , Receptor IGF Tipo 2/metabolismo , Proteínas Recombinantes de Fusión/administración & dosificación , Acetilglucosaminidasa/uso terapéutico , Administración Intravenosa , Animales , Modelos Animales de Enfermedad , Terapia de Reemplazo Enzimático , Femenino , Infusiones Intraventriculares , Factor II del Crecimiento Similar a la Insulina/uso terapéutico , Masculino , Ratones , Ratones Transgénicos , Mucopolisacaridosis III/genética , Primates , Proteínas Recombinantes de Fusión/uso terapéutico , Investigación Biomédica Traslacional
6.
AAPS PharmSciTech ; 20(2): 50, 2019 Jan 07.
Artículo en Inglés | MEDLINE | ID: mdl-30617637

RESUMEN

Gene therapy involving p11 cDNA has been thought to be a futuristic approach for the effective management of depression as the existing treatment regimen presents many issues regarding late onset of action, patient withdrawal and their side effects. For the effective transfection of p11 gene intracellularly, two cationic lipids based on phospholipid DOPE conjugated to basic amino acids histidine and arginine were synthesised, used for liposome formulation and evaluated for their ability as gene delivery vectors. They were further converted using IGF-II mAb into immunoliposomes for CNS targeting and mAb conjugation to liposomes were characterised by SDS-PAGE. They were further analysed by in vitro characterisation studies that include erythrocyte aggregation study, electrolyte-induced study, heparin compatibility study and serum stability studies. SHSY5Y cells were used for conducting cytotoxicity of synthesised lipids and live imaging of cell uptake for 25 min. Finally, the brain distribution studies and western blot were carried out in animals to evaluate them for their BBB permeation ability and effects on p11 protein which is believed to be a culprit. These formulated liposomes from synthesised lipids offer a promising approach for the treatment of depression.


Asunto(s)
Encéfalo/metabolismo , Péptidos de Penetración Celular/genética , Depresión/genética , Terapia Genética/métodos , Factor II del Crecimiento Similar a la Insulina/genética , Nanopartículas/metabolismo , Animales , Línea Celular Tumoral , Supervivencia Celular/fisiología , Péptidos de Penetración Celular/administración & dosificación , Péptidos de Penetración Celular/metabolismo , Depresión/metabolismo , Depresión/terapia , Marcación de Gen/métodos , Técnicas de Transferencia de Gen , Humanos , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Factor II del Crecimiento Similar a la Insulina/metabolismo , Liposomas/química , Masculino , Ratones , Nanopartículas/administración & dosificación , Ratas , Ratas Sprague-Dawley
7.
Reproduction ; 153(3): 327-340, 2017 03.
Artículo en Inglés | MEDLINE | ID: mdl-28073983

RESUMEN

The preimplantation embryo in vivo is exposed to numerous growth factors in the female reproductive tract, which are not recapitulated in embryo culture media in vitro The IGF2 and plasminogen activator systems facilitate blastocyst development. We hypothesized that the addition of IGF2 in combination with urokinase plasminogen activator (uPA) and plasminogen could improve rates of blastocyst hatching and implantation in mice. B6BcF1 and CBAB6F2 mouse embryos were divided into one of four supplemented culture media treatment groups: (1) control (media only); (2) 12.5 nM IGF2; (3) 10 µg/mL uPA and 5 µg/mL plasminogen; or (4) a combination of IGF2, uPA and plasminogen treatments. Embryo development to blastocyst stage and hatching were assessed before transfer to pseudopregnant recipient females and implantation, pregnancy rates and postnatal growth were assessed. After 90.5 h of culture, IGF2 + U + P treatment increased the percentage of B6BcF1 embryos that were hatching/hatched and percentage developing to blastocyst stage compared with controls (P < 0.02). Following B6BcF1 embryo transfer, IGF2 + U + P treatment increased implantation sites at day 8 of pregnancy compared with controls (P < 0.05). Replication in the CBAB6F2 mouse strain showed significant improvements in pregnancy rates at days 8 and 18 but not in blastocyst development. No adverse effects were seen on gestational age, litter size or birthweight, or the reproductive capacity of offspring of IGF2 + U + P treated embryos. For embryos susceptible to detrimental effects of in vitro culture, IGF2, uPA and plasminogen supplementation of culture media can improve pregnancy success, but the effect of treatment is dependent on the mouse strain.


Asunto(s)
Blastocisto/citología , Medios de Cultivo/farmacología , Fertilización In Vitro/efectos de los fármacos , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Plasminógeno/administración & dosificación , Índice de Embarazo , Activador de Plasminógeno de Tipo Uroquinasa/administración & dosificación , Animales , Blastocisto/efectos de los fármacos , Técnicas de Cultivo de Embriones , Implantación del Embrión/efectos de los fármacos , Transferencia de Embrión , Desarrollo Embrionario/efectos de los fármacos , Femenino , Ratones , Ratones Endogámicos C57BL , Embarazo
8.
Neurobiol Aging ; 44: 9-21, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-27318130

RESUMEN

Aging is accompanied by declines in memory performance, and particularly affects memories that rely on hippocampal-cortical systems, such as episodic and explicit. With aged populations significantly increasing, the need for preventing or rescuing memory deficits is pressing. However, effective treatments are lacking. Here, we show that the level of the mature form of insulin-like growth factor 2 (IGF-2), a peptide regulated in the hippocampus by learning, required for memory consolidation and a promoter of memory enhancement in young adult rodents, is significantly reduced in hippocampal synapses of aged rats. By contrast, the hippocampal level of the immature form proIGF-2 is increased, suggesting an aging-related deficit in IGF-2 processing. In agreement, aged compared to young adult rats are deficient in the activity of proprotein convertase 2, an enzyme that likely mediates IGF-2 posttranslational processing. Hippocampal administration of the recombinant, mature form of IGF-2 rescues hippocampal-dependent memory deficits and working memory impairment in aged rats. Thus, IGF-2 may represent a novel therapeutic avenue for preventing or reversing aging-related cognitive impairments.


Asunto(s)
Envejecimiento/psicología , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Factor II del Crecimiento Similar a la Insulina/fisiología , Trastornos de la Memoria/etiología , Trastornos de la Memoria/prevención & control , Memoria , Animales , Hipocampo/metabolismo , Factor II del Crecimiento Similar a la Insulina/deficiencia , Factor II del Crecimiento Similar a la Insulina/metabolismo , Masculino , Memoria a Corto Plazo , Terapia Molecular Dirigida , Proproteína Convertasa 2/metabolismo , Procesamiento Proteico-Postraduccional , Ratas , Ratas Endogámicas F344 , Proteínas Recombinantes/administración & dosificación
9.
Am J Physiol Endocrinol Metab ; 310(1): E24-31, 2016 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-26530156

RESUMEN

Enhancing placental insulin-like growth factor (IGF) availability appears to be an attractive strategy for improving outcomes in fetal growth restriction (FGR). Our approach was the novel use of [Leu(27)]IGF-II, a human IGF-II analog that binds the IGF-II clearance receptor IGF-IIR in fetal growth-restricted (FGR) mice. We hypothesized that the impact of [Leu(27)]IGF-II infusion in C57BL/6J (wild-type) and endothelial nitric oxide synthase knockout (eNOS(-/-); FGR) mice would be to enhance fetal growth and investigated this from mid- to late gestation; 1 mg·kg(-1)·day(-1) [Leu(27)]IGF-II was delivered via a subcutaneous miniosmotic pump from E12.5 to E18.5. Fetal and placental weights recorded at E18.5 were used to generate frequency distribution curves; fetuses <5th centile were deemed growth restricted. Placentas were harvested for immunohistochemical analysis of the IGF system, and maternal serum was collected for measurement of exogenously administered IGF-II. In WT pregnancies, [Leu(27)]IGF-II treatment halved the number of FGR fetuses, reduced fetal(P = 0.028) and placental weight variations (P = 0.0032), and increased the numbers of pups close to the mean fetal weight (131 vs. 112 pups within 1 SD). Mixed-model analysis confirmed litter size to be negatively correlated with fetal and placental weight and showed that [Leu(27)]IGF-II preferentially improved fetal weight in the largest litters, as defined by number. Unidirectional (14C)MeAIB transfer per gram placenta (System A amino acid transporter activity) was inversely correlated with fetal weight in [Leu(27)]IGF-II-treated WT animals (P < 0.01). In eNOS(-/-) mice, [Leu(27)]IGF-II reduced the number of FGR fetuses(1 vs. 5 in the untreated group). The observed reduction in FGR pup numbers in both C57 and eNOS(-/-) litters suggests the use of this analog as a means of standardizing and rescuing fetal growth, preferentially in the smallest offspring.


Asunto(s)
Desarrollo Fetal/efectos de los fármacos , Retardo del Crecimiento Fetal/patología , Factor II del Crecimiento Similar a la Insulina/análogos & derivados , Animales , Modelos Animales de Enfermedad , Embrión de Mamíferos , Femenino , Retardo del Crecimiento Fetal/tratamiento farmacológico , Humanos , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Factor II del Crecimiento Similar a la Insulina/genética , Factor II del Crecimiento Similar a la Insulina/farmacología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Óxido Nítrico Sintasa de Tipo III/genética , Embarazo , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/farmacología
10.
Brain Res ; 1622: 466-73, 2015 Oct 05.
Artículo en Inglés | MEDLINE | ID: mdl-26168901

RESUMEN

Memory consolidation is an important process for the formation of long-term memory. We have previously reported that mature brain-derived neurotrophic factor enhances memory consolidation within 9h after initial learning. Recent studies suggest that insulin-like growth factor 2 (IGF2) significantly enhances memory consolidation and prevents forgetting. Thus, we hypothesized that IGF2 exerts its activity on cognitive performance in a time-dependent manner as observed in our previous study. In the one-trial step-through inhibitory avoidance task, we demonstrate that a bilateral injection of IGF2 into the dorsal hippocampus 6 or 9 h after training significantly enhanced the step-through latencies compared with the vehicle-treated controls in the retention trial, which was conducted 24 h after the acquisition trial. However, 12h post-training, IGF2 injection did not increase the step-through latencies. Intriguingly, in the retention trial at 21 days after the training, hippocampal IGF2 injection 6, 9 or 12 h after the acquisition trial significantly increased the step-through latencies compared with the vehicle-treated controls. IGF2 administration at 9 h and 12 h after the acquisition trial significantly increased discrimination index and exploration time on the novel-located object in the test trial at 24 h and 21 days, respectively, after the acquisition trial in the novel location recognition task. In addition, IGF2-induced an increase in the step-through latencies in the retention trial 24 h or 21 days, respectively, after the initial learning was completely abolished by co-injected anti-IGF2 receptor antibody. These results suggest that IGF2 enhances memory consolidation within 9h after initial learning, and increased IGF2 within the 12 h after the acquisition trial, which represents a delayed consolidation phase, is also critical for memory persistence.


Asunto(s)
Hipocampo/efectos de los fármacos , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Consolidación de la Memoria/efectos de los fármacos , Nootrópicos/administración & dosificación , Proteínas Recombinantes/administración & dosificación , Animales , Reacción de Prevención/efectos de los fármacos , Reacción de Prevención/fisiología , Discriminación en Psicología/efectos de los fármacos , Discriminación en Psicología/fisiología , Conducta Exploratoria/efectos de los fármacos , Conducta Exploratoria/fisiología , Hipocampo/metabolismo , Masculino , Consolidación de la Memoria/fisiología , Ratones Endogámicos ICR , Pruebas Neuropsicológicas , Receptor IGF Tipo 2/metabolismo , Conducta Espacial/efectos de los fármacos , Conducta Espacial/fisiología , Factores de Tiempo
11.
Basic Clin Pharmacol Toxicol ; 115(5): 438-47, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24751184

RESUMEN

In an open-chest porcine model, we examined whether myocardial pharmacological conditioning at the time of reperfusion with low-dose insulin or insulin-like growth factor 2 (IGF2), not affecting serum glucose levels, could reduce infarct size and improve functional recovery. Two groups of anaesthetized pigs with either 60 or 40 min. of left anterior descending artery occlusion (total n = 42) were randomized to receive either 0.9% saline, insulin or IGF2 infusion for 15 min., starting 5 min. before a 180-min. reperfusion period. Repeated fluorescent microsphere injections were used to confirm ischaemia and reperfusion. Area at risk and infarct size was determined with Evans blue and triphenyltetrazolium chloride staining. Local myocardial function was evaluated with multi-layer radial tissue Doppler strain and speckle-tracking strain from epicardial echocardiography. Western blotting and TUNEL staining were performed to explore apoptosis. Infarct size did not differ between treatment groups and was 56.7 ± 6.8%, 49.7 ± 9.6%, 56.2 ± 8.0% of area at risk for control, insulin and IGF2 group, respectively, in the 60-min. occlusion series. Corresponding values were 45.6 ± 6.0%, 48.4 ± 7.2% and 34.1 ± 5.8% after 40-min. occlusion. Global and local cardiac function did not differ between treatment groups. No differences related to treatment could be found in myocardial tissue cleaved caspase-3 content or the degree of TUNEL staining. Reperfusion therapy with low-dose insulin or with IGF2 neither reduced infarct size nor improved function in reperfused myocardium in this in vivo porcine model.


Asunto(s)
Factor II del Crecimiento Similar a la Insulina/farmacología , Insulina/farmacología , Infarto del Miocardio/prevención & control , Daño por Reperfusión Miocárdica/tratamiento farmacológico , Animales , Apoptosis/efectos de los fármacos , Western Blotting , Modelos Animales de Enfermedad , Ecocardiografía , Femenino , Etiquetado Corte-Fin in Situ , Insulina/administración & dosificación , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Masculino , Porcinos , Factores de Tiempo
12.
PLoS One ; 9(4): e94287, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24732467

RESUMEN

The development of an effective therapy for Alzheimer's disease (AD) is a major challenge to biomedical sciences. Because much of early AD pathophysiology includes hippocampal abnormalities, a viable treatment strategy might be to use trophic factors that support hippocampal integrity and function. IGF2 is an attractive candidate as it acts in the hippocampus to enhance memory consolidation, stimulate adult neurogenesis and upregulate cholinergic marker expression and acetylcholine (ACh) release. We performed a seven-day intracerebroventricular infusion of IGF2 in transgenic APPswe.PS1dE9 AD model mice that express green fluorescent protein in cholinergic neurons (APP.PS1/CHGFP) and in wild type WT/CHGFP littermates at 6 months of age representing early AD-like disease. IGF2 reduced the number of hippocampal Aß40- and Aß42-positive amyloid plaques in APP.PS1/CHGFP mice. Moreover, IGF2 increased hippocampal protein levels of the ACh-synthesizing enzyme, choline acetyltransferase in both WT/CHGFP and APP.PS1/CHGFP mice. The latter effect was likely mediated by increased protein expression of the cholinergic differentiating factor, BMP9, observed in IGF2-treated mice as compared to controls. IGF2 also increased the protein levels of hippocampal NGF, BDNF, NT3 and IGF1 and of doublecortin, a marker of neurogenesis. These data show that IGF2 administration is effective in reversing and preventing several pathophysiologic processes associated with AD and suggest that IGF2 may constitute a therapeutic target for AD.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Amiloidosis/patología , Neuronas Colinérgicas/metabolismo , Factor 2 de Diferenciación de Crecimiento/metabolismo , Hipocampo/metabolismo , Factor II del Crecimiento Similar a la Insulina/metabolismo , Factores de Crecimiento Nervioso/metabolismo , Receptores de Activinas Tipo I/metabolismo , Receptores de Activinas Tipo II , Enfermedad de Alzheimer/complicaciones , Enfermedad de Alzheimer/patología , Enfermedad de Alzheimer/fisiopatología , Péptidos beta-Amiloides/metabolismo , Amiloidosis/complicaciones , Amiloidosis/fisiopatología , Animales , Biomarcadores/metabolismo , Colina O-Acetiltransferasa/metabolismo , Neuronas Colinérgicas/patología , Modelos Animales de Enfermedad , Proteínas de Dominio Doblecortina , Proteína Ácida Fibrilar de la Glía/metabolismo , Gliosis/complicaciones , Gliosis/patología , Gliosis/fisiopatología , Hipocampo/enzimología , Hipocampo/patología , Humanos , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Ratones , Ratones Transgénicos , Proteínas Asociadas a Microtúbulos/metabolismo , Neurogénesis , Neuropéptidos/metabolismo , Placa Amiloide/complicaciones , Placa Amiloide/patología , Placa Amiloide/fisiopatología
13.
Growth Horm IGF Res ; 23(1-2): 37-44, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23333247

RESUMEN

OBJECTIVE: Evaluate the possible role of IGF-II alone or in association with FSH on in vitro development of isolated caprine preantral follicles. METHODS: Preantral follicles (≥150 µm) were isolated from goat ovaries and cultured for 18 days in basic αMEM medium (control) or supplemented with IGF-II alone at 20 or 50 ng/ml, named IGF20 and IGF50, respectively, or in combination with recombinant FSH (FSH, IGF20F or IGF50F). During in vitro culture, the follicles were analyzed by using morphology criteria, antrum formation and growth rate as parameters. After 18 days of follicular culture, oocytes equal to or larger than 110 µm were used for in vitro maturation (IVM). Oocyte viability and meiosis resumption were assessed by fluorescence microscopy after labeling with calcein-AM, ethidium homodimer and Hoechst 33342. RESULTS: The IGF20 treatment was the only treatment capable of maintaining the percentage of morphologically normal follicles from D0 until D6 and from D12 to D18 (p>0.05), while in all other treatments the percentage of morphologically normal follicles decreased progressively during 18 days of in vitro culture (p<0.05). At D18, all treatments with IGF-II or FSH resulted in a significantly higher percentage of normal follicles when compared to αMEM alone. The IGF50F treatment provided a significantly higher early antrum formation rate when compared to αMEM and FSH alone. The addition of IGF-II alone (20 or 50 ng/ml) or in combination with FSH prevented oocyte degeneration after IVM. Moreover, the FSH treatment demonstrated a lower percentage of oocyte degeneration when compared to control (4.35% vs. 26.3%, respectively; p<0.05). Regarding meiosis resumption, the IGF20F treatment was the only treatment that significantly differed from αMEM alone. All treatments except the control (αMEM alone) presented oocytes at metaphase II. CONCLUSION: IGF-II associated with FSH stimulated in vitro follicular development, oocyte viability and meiotic resumption of caprine oocytes after IVM.


Asunto(s)
Hormona Folículo Estimulante/farmacología , Cabras , Técnicas de Maduración In Vitro de los Oocitos/métodos , Factor II del Crecimiento Similar a la Insulina/farmacología , Oocitos/efectos de los fármacos , Folículo Ovárico/efectos de los fármacos , Animales , Tamaño de la Célula/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Medios de Cultivo/farmacología , Femenino , Hormona Folículo Estimulante/administración & dosificación , Cabras/fisiología , Técnicas de Maduración In Vitro de los Oocitos/veterinaria , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Oocitos/citología , Oocitos/fisiología , Oogénesis/efectos de los fármacos , Oogénesis/fisiología , Folículo Ovárico/citología , Folículo Ovárico/fisiología
14.
J Chin Med Assoc ; 75(10): 494-500, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23089400

RESUMEN

BACKGROUND: For devising potential clinical approaches for limb length discrepancies, we examined local administration of insulin-like growth factor 2 (IGF2). METHODS: C57/BL/6 mice (∼ 8 weeks old) were used in this study, and the mice were separated into two groups: an IGF2-treated group and a placebo group. In the IGF2-treated group, IGF2 was locally administered into the distal epiphysis of the left femur, and the right femur was used as a contralateral control. In the placebo group, saline was administered to the left femur as a vehicle control. The left and right tibiae, without any direct intervention, were employed as negative controls. The dosage of IGF2 was 100 µg/kg/day for 5 consecutive days, and bone samples were harvested on Day 14. Microcomputed tomography images did not show any anomaly at the IGF2 or saline injection sites. RESULTS: In comparison with the vehicle control as well as the contralateral control, the results revealed that IGF2 significantly lengthened the treated femur, with an elevation of bone mineral density (BMD) as well as bone mineral content (BMC). The increase in the femoral length of the IGF2-treated left limb was 1.6% (p < 0.05) to the vehicle control, and 1.7% (p < 0.05) to the contralateral control. However, the length, BMD, and BMC of the tibiae were not affected by administration of IGF2 or saline. Western blotting analysis demonstrated that this administration of IGF2 upregulated phosphorylation of an extracellular signal-regulated kinase in the treated femur. CONCLUSION: The current study supports for the first time the potential effectiveness of administration of IGF2 in adjusting limb length discrepancy.


Asunto(s)
Alargamiento Óseo , Factor II del Crecimiento Similar a la Insulina/farmacología , Animales , Fémur/efectos de los fármacos , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Ratones , Ratones Endogámicos C57BL
15.
J Transl Med ; 9: 103, 2011 Jul 06.
Artículo en Inglés | MEDLINE | ID: mdl-21733157

RESUMEN

BACKGROUND: GH and IGFs serum levels decline with age. Age-related changes appear to be associated to decreases in these anabolic hormones. We have previously demonstrated that IGF-I replacement therapy improves insulin resistance, lipid metabolism and reduces oxidative damage (in brain and liver) in aging rats. Using the same experimental model, the aim of this work was to study whether the exogenous administration of IGF-II, at low doses, acts analogous to IGF-I in aging rats. METHODS: Three experimental groups were included in this study: young healthy controls (yCO, 17 weeks old); untreated old rats (O, 103 weeks old); and aging rats treated with IGF-II (O+IGF-II, 2 µg * 100 g body weight⁻¹ * day⁻¹) for 30 days. Analytical parameters were determined in serum by routine laboratory methods using an autoanalyzer (Cobas Mira; Roche Diagnostic System, Basel, Switzerland). Serum levels of hormones (testosterone, IGF-I and insulin) were assessed by RIA. Serum Total Antioxidant Status was evaluated using a colorimetric assay. Mitochondrial membrane potential was evaluated using rhodamine 123 dye (adding different substrates to determine the different states). ATP synthesis in isolated mitochondria was determined by an enzymatic method. RESULTS: Compared with young controls, untreated old rats showed a reduction of IGF-I and testosterone levels with a decrease of serum total antioxidant status (TAS). IGF-II therapy improved serum antioxidant capability without modifying testosterone and IGF-I circulating concentrations. In addition, IGF-II treatment reduced oxidative damage in brain and liver, improving antioxidant enzyme activities and mitochondrial function. IGF-II was also able to reduce cholesterol and triglycerides levels increasing free fatty acids concentrations. CONCLUSIONS: We demonstrate that low doses of IGF-II induce hepatoprotective, neuroprotective and metabolic effects, improving mitochondrial function, without affecting testosterone and IGF-I levels.


Asunto(s)
Envejecimiento/efectos de los fármacos , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Factor II del Crecimiento Similar a la Insulina/farmacología , Hígado/efectos de los fármacos , Sistema Nervioso/efectos de los fármacos , Sustancias Protectoras/farmacología , Envejecimiento/metabolismo , Animales , Antioxidantes/metabolismo , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Relación Dosis-Respuesta a Droga , Glucosa/metabolismo , Hormonas/metabolismo , Humanos , Insulina/sangre , Factor I del Crecimiento Similar a la Insulina/metabolismo , Metabolismo de los Lípidos/efectos de los fármacos , Peroxidación de Lípido/efectos de los fármacos , Hígado/enzimología , Masculino , Malondialdehído/metabolismo , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Ratones , Mitocondrias Hepáticas/efectos de los fármacos , Mitocondrias Hepáticas/metabolismo , Sistema Nervioso/metabolismo , Estrés Oxidativo/efectos de los fármacos , Carbonilación Proteica/efectos de los fármacos , Ratas , Ratas Wistar , Testosterona/sangre
16.
J Transl Med ; 9: 123, 2011 Jul 28.
Artículo en Inglés | MEDLINE | ID: mdl-21798010

RESUMEN

BACKGROUND: Serum IGF-I and IGF-II levels decline with age. IGF-I replacement therapy reduces the impact of age in rats. We have recently reported that IGF-II is able to act, in part, as an analogous of IGF-I in aging rats reducing oxidative damage in brain and liver associated with a normalization of antioxidant enzyme activities. Since mitochondria seem to be the most important cellular target of IGF-I, the aim of this work was to investigate whether the cytoprotective actions of IGF-II therapy are mediated by mitochondrial protection. METHODS: Three groups of rats were included in the experimental protocol young controls (17 weeks old); untreated old rats (103 weeks old); and aging rats (103 weeks old) treated with IGF-II (2 µg/100 g body weight and day) for 30 days. RESULTS: Compared with young controls, untreated old rats showed an increase of oxidative damage in isolated mitochondria with a dysfunction characterized by: reduction of mitochondrial membrane potential (MMP) and ATP synthesis and increase of intramitochondrial free radicals production and proton leak rates. In addition, in untreated old rats mitochondrial respiration was not blocked by atractyloside. In accordance, old rats showed an overexpression of the active fragment of caspases 3 and 9 in liver homogenates. IGF-II therapy corrected all of these parameters of mitochondrial dysfunction and reduced activation of caspases. CONCLUSIONS: The cytoprotective effects of IGF-II are related to mitochondrial protection leading to increased ATP production reducing free radical generation, oxidative damage and apoptosis.


Asunto(s)
Envejecimiento/efectos de los fármacos , Envejecimiento/metabolismo , Factor II del Crecimiento Similar a la Insulina/farmacología , Mitocondrias Hepáticas/efectos de los fármacos , Mitocondrias Hepáticas/metabolismo , Complejos de ATP Sintetasa/metabolismo , Animales , Antioxidantes/metabolismo , Atractilósido/farmacología , Caspasa 3/metabolismo , Caspasa 9 , Complejo IV de Transporte de Electrones/metabolismo , Humanos , Peróxido de Hidrógeno/metabolismo , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Masculino , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Mitocondrias Hepáticas/enzimología , Estrés Oxidativo/efectos de los fármacos , Consumo de Oxígeno/efectos de los fármacos , Protones , Ratas , Ratas Wistar
17.
Graefes Arch Clin Exp Ophthalmol ; 248(4): 519-25, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20135141

RESUMEN

OBJECTIVE: By investigating the effects of recombinant human IGF-2 (rhIGF-2) on the diopter, axial eye length and the expression of IGF-2 in non-form-deprivation (FD) and FD eyes of guinea pig, we tried to elucidate the relationship between the effects of rhIGF-2 on eye growth and FD in guinea pig. METHODS: Eighty 3-week-old guinea pigs were included in the study, which were divided into two groups randomly. Group A (n = 40) was the non-FD group, Thirty-two guinea pigs received intravitreal injections of either 1 ng, 10 ng, 100 ng rhIGF-2 or bovine serum albumin (BSA) to the right eye; eight guinea pigs who received no intravitreal injections served as control. Group B (n = 40) was the FD group; the right eyes were form-deprived, and received the same disposals as group A. The diopter and the axial eye length of all guinea pigs were measured at day 14. The expression of IGF-2 in the retina was measured by Western blot. RESULTS: After 14 days, FD eyes were high myopia. The axial length of FD eyes was significant for longer than that of non-FD eyes. The expression of IGF-2 in the retina of FD eyes was up-regulated. In non-FD group, there was no significant difference in the diopter and axial eye length among rhIGF-2 injection eyes, BSA injection eyes and control eyes, but the expression of IGF-2 in the retina of 10 ng and 100 ng rhIGF-2 injection eyes was obviously down-regulated. In the FDM (form-deprivation myopia) group, the myopic diopter and axial eye length increased in 10 ng and 100 ng rhIGF-2 injection eyes compared with those in BSA injection eyes and control eyes. The level of IGF-2 expression in the retina of 10 ng and 100 ng rhIGF-2 injection eyes was obviously down-regulated. The diopter and expression of IGF-2 in the retina of rhIGF-2 injection eyes was negatively correlated with the dose of each injection, which was positively correlated with the axial length. CONCLUSION: RhIGF-2 intravitreous injection does not affect the diopter and axial length in non-FD eyes of guinea pig, while it can induce a significant increase in myopic diopter and axial length of FD eyes. RhIGF-2 can promote the development of FDM on the condition of FD.


Asunto(s)
Ojo/crecimiento & desarrollo , Factor II del Crecimiento Similar a la Insulina/metabolismo , Miopía/metabolismo , Proteínas Recombinantes/metabolismo , Retina/metabolismo , Animales , Western Blotting , Cobayas , Inyecciones , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Miopía/etiología , Proteínas Recombinantes/administración & dosificación , Privación Sensorial , Cuerpo Vítreo
18.
Theriogenology ; 73(5): 595-604, 2010 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-20035987

RESUMEN

This study examined the influence of the following growth factors and cytokines on early embryonic development: insulin-like growth factors I and II (IGF-I, IGF-II), basic fibroblast growth factor (bFGF), transforming growth factor (TGF-beta), granulocyte-macrophage colony-stimulating factor (GM-CSF), and leukemia inhibitory factor (LIF). Synthetic oviduct fluid (SOF) was used as the culture medium. We studied the development of bovine embryos produced in vitro and cultured until Day 9 after fertilization. TGF-beta1, bFGF, GM-CSF, and LIF used on their own significantly improved the yield of hatched blastocysts. IGF-I, bFGF, TGF-beta1, GM-CSF, and LIF significantly accelerated embryonic development, especially the change from the expanded blastocyst to hatched blastocyst stages. Use of a combination of these growth factors and cytokines (GF-CYK) in SOF medium produced higher percentages of blastocysts and hatched blastocysts than did use of SOF alone (45% and 22% vs. 24% and 12%; P<0.05) on Day 8 after in vitro fertilization and similar results to use of SOF+10% fetal calf serum (38% and 16%, at the same stages, respectively). The averages of total cells, inner cell mass cells, and trophectoderm cells of exclusively in vitro Day-8 blastocysts for pooled GF-CYK treatments were higher than those for SOF and similar to those for fetal calf serum. The presence of these growth factors and cytokines in the embryo culture medium therefore has a combined stimulatory action on embryonic development; in particular through an increase in hatching rate and in the number of cells of both the inner cell mass and trophoblast. These results are the first to demonstrate that use of a combination of recombinant growth factors and cytokine, as IGF-I, IGF-II, bFGF, TGF-beta1, LIF, and GM-CSF, produces similar results to 10% fetal calf serum for the development of in vitro-produced bovine embryos. This entirely synthetic method of embryo culture has undeniable advantages for the biosecurity of embryo transfer.


Asunto(s)
Desarrollo Embrionario/efectos de los fármacos , Factor 2 de Crecimiento de Fibroblastos/administración & dosificación , Factor Estimulante de Colonias de Granulocitos y Macrófagos/administración & dosificación , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Factor I del Crecimiento Similar a la Insulina/administración & dosificación , Factor Inhibidor de Leucemia/administración & dosificación , Factor de Crecimiento Transformador beta1/administración & dosificación , Animales , Bovinos , Medio de Cultivo Libre de Suero/farmacología , Combinación de Medicamentos , Técnicas de Cultivo de Embriones , Embrión de Mamíferos , Femenino , Fertilización In Vitro , Factor 2 de Crecimiento de Fibroblastos/farmacología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/farmacología , Factor I del Crecimiento Similar a la Insulina/farmacología , Factor II del Crecimiento Similar a la Insulina/farmacología , Factor Inhibidor de Leucemia/farmacología , Masculino , Factor de Crecimiento Transformador beta1/farmacología
19.
Anticancer Res ; 29(7): 2467-72, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19596915

RESUMEN

JNK-interacting protein 1 (JIP-1) is an important scaffolding protein in the JNK signalling pathway. It is also believed to play a role in the mediation of mitogenic messages from the plasma membrane to the cell interior. Previous studies suggest that the JIP-gene is co-regulated with the insulin-like growth factor II (IGF II) gene, thereby contributing to the growth stimulatory effects of this potent growth factor. The striking coexpression of these two genes was found in murine fetuses as well as in primary human embryonic tumours. When six primary Wilms tumours were examined, the two genes showed a high degree of co-variation in the sense that high expression of IGF II was followed by high expression of JIP-1 and vice versa. However, when the human Wilms tumour cell line WCCS-1 was examined, a very modest intrinsic expression of IGF II was accompanied by a moderate expression of JIP-1. When exogenous IGF II was added, which has previously been shown to induce apoptosis in this cell line, the JIP-1 expression increased. These data suggest that JIP-1 has a more complex role in the regulation of proliferation as well as programmed cell death.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/metabolismo , Factor II del Crecimiento Similar a la Insulina/metabolismo , Tumor de Wilms/metabolismo , Proteínas Adaptadoras Transductoras de Señales/genética , Animales , Línea Celular Tumoral , Regulación Neoplásica de la Expresión Génica , Humanos , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Factor II del Crecimiento Similar a la Insulina/genética , Ratones , Unión Proteica , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/metabolismo , Tumor de Wilms/patología
20.
Acta Histochem ; 110(6): 451-61, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18405944

RESUMEN

The sole structural determinant for the differential ability of the insulin-like growth factors (IGF-I and IGF-II) to induce autophosphorylation of specific insulin receptor (IR) tyrosine residues and activate downstream signaling molecules is the C domain. The IR is structurally related to the type I insulin-like growth factor receptor (IGF-IR). This study aimed to identify the presence of IGF receptors by which the IGF-II C-peptide could mediate its effects in the frog (Rana ridibunda) adrenal glands and to observe whether injection of IGF-II C-peptide affects the function of adrenal steroidogenic cells using light and transmission electron microscopy and by the evaluation of the immunoreactivity of steroidogenic acute regulatory protein (StAR). After IGF-II C-peptide injection, there was a reduction of StAR protein immunoreactivity levels, an accumulation of large lipid droplets in close contact with each other, and an induction of proliferation of the steroidogenic cells. These results indicate a possible role of IGF-II C-peptide in steroidogenic cell function and in induction of steroidogenesis. The detection in this study of IGF-I receptor (IGF-IR) immunoreactivity in frog adrenal glands also indicates that the metabolic and mitogenic effects of IGF-II C-peptide in these glands may occur via the IGF-IR.


Asunto(s)
Glándulas Suprarrenales/citología , Factor II del Crecimiento Similar a la Insulina/farmacología , Glándulas Suprarrenales/efectos de los fármacos , Glándulas Suprarrenales/ultraestructura , Animales , División Celular/efectos de los fármacos , Inmunohistoquímica , Inyecciones , Factor II del Crecimiento Similar a la Insulina/administración & dosificación , Luz , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/farmacología , Fosfoproteínas/farmacocinética , Fosfoproteínas/farmacología , Rana ridibunda
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...